Abstract
Antibody-mediated acute rejection (AbAR) is one of the primary causes of graft impairment in kidney transplant recipients. Deoxyspergualin (DSG), which displays an antiproliferative action against antigen-stimulated B cells inhibiting antibody production, may be effective to rescue AbAR in combination with plasmapheresis by suppressing antibody production and elimination. In the present study, we report our experience with DSG/plasmapheresis therapy for the treatment of AbAR. Five kidney transplant patients experienced a steroid-resistant acute rejection requiring dialysis followed by an AbAR that was confirmed by biopsy and flow cytometry crossmatch (FCXM) results. DSG was administration at 3 mg/kg per day for 10 days with plasmapheresis reduce antidonor antibody. Treatment outcome, effectiveness, and adverse events were examined; in two cases sequential FCXM examinations were performed to evaluate antibody status. All five patients received DSG/plasmapheresis therapy. The number of plasmapheresis treatments ranged from 1 to 9 according to treatment outcomes. Four patients recovered graft function following treatment; whereas one showed no response to the treatment, and the graft was lost. No serious side effects or infections were observed during or after treatment. Monitoring of sequential FCXM correlated with the clinical course. AbAR shows a worse prognosis than cellular rejection. It is refractory to conventional antirejection therapy. In the present study, DSG/plasmapheresis therapy was effective in four of five patients (80%) with AbAR. It may be considered the first choice of treatment for cases of acute humoral rejection.
| Original language | English |
|---|---|
| Pages (from-to) | 930-933 |
| Number of pages | 4 |
| Journal | Transplantation Proceedings |
| Volume | 37 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2005 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Transplantation
Cite this
Combined therapy of deoxyspergualin and plasmapheresis : A useful treatment for antibody-mediated acute rejection after kidney transplantation. / Nojima, M.; Yoshimoto, T.; Nakao, Atsunori; Maruyama, T.; Takiuchi, H.; Izumi, M.; Hashimoto, M.; Kyo, M.; Shima, H.
In: Transplantation Proceedings, Vol. 37, No. 2, 03.2005, p. 930-933.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combined therapy of deoxyspergualin and plasmapheresis
T2 - A useful treatment for antibody-mediated acute rejection after kidney transplantation
AU - Nojima, M.
AU - Yoshimoto, T.
AU - Nakao, Atsunori
AU - Maruyama, T.
AU - Takiuchi, H.
AU - Izumi, M.
AU - Hashimoto, M.
AU - Kyo, M.
AU - Shima, H.
PY - 2005/3
Y1 - 2005/3
N2 - Antibody-mediated acute rejection (AbAR) is one of the primary causes of graft impairment in kidney transplant recipients. Deoxyspergualin (DSG), which displays an antiproliferative action against antigen-stimulated B cells inhibiting antibody production, may be effective to rescue AbAR in combination with plasmapheresis by suppressing antibody production and elimination. In the present study, we report our experience with DSG/plasmapheresis therapy for the treatment of AbAR. Five kidney transplant patients experienced a steroid-resistant acute rejection requiring dialysis followed by an AbAR that was confirmed by biopsy and flow cytometry crossmatch (FCXM) results. DSG was administration at 3 mg/kg per day for 10 days with plasmapheresis reduce antidonor antibody. Treatment outcome, effectiveness, and adverse events were examined; in two cases sequential FCXM examinations were performed to evaluate antibody status. All five patients received DSG/plasmapheresis therapy. The number of plasmapheresis treatments ranged from 1 to 9 according to treatment outcomes. Four patients recovered graft function following treatment; whereas one showed no response to the treatment, and the graft was lost. No serious side effects or infections were observed during or after treatment. Monitoring of sequential FCXM correlated with the clinical course. AbAR shows a worse prognosis than cellular rejection. It is refractory to conventional antirejection therapy. In the present study, DSG/plasmapheresis therapy was effective in four of five patients (80%) with AbAR. It may be considered the first choice of treatment for cases of acute humoral rejection.
AB - Antibody-mediated acute rejection (AbAR) is one of the primary causes of graft impairment in kidney transplant recipients. Deoxyspergualin (DSG), which displays an antiproliferative action against antigen-stimulated B cells inhibiting antibody production, may be effective to rescue AbAR in combination with plasmapheresis by suppressing antibody production and elimination. In the present study, we report our experience with DSG/plasmapheresis therapy for the treatment of AbAR. Five kidney transplant patients experienced a steroid-resistant acute rejection requiring dialysis followed by an AbAR that was confirmed by biopsy and flow cytometry crossmatch (FCXM) results. DSG was administration at 3 mg/kg per day for 10 days with plasmapheresis reduce antidonor antibody. Treatment outcome, effectiveness, and adverse events were examined; in two cases sequential FCXM examinations were performed to evaluate antibody status. All five patients received DSG/plasmapheresis therapy. The number of plasmapheresis treatments ranged from 1 to 9 according to treatment outcomes. Four patients recovered graft function following treatment; whereas one showed no response to the treatment, and the graft was lost. No serious side effects or infections were observed during or after treatment. Monitoring of sequential FCXM correlated with the clinical course. AbAR shows a worse prognosis than cellular rejection. It is refractory to conventional antirejection therapy. In the present study, DSG/plasmapheresis therapy was effective in four of five patients (80%) with AbAR. It may be considered the first choice of treatment for cases of acute humoral rejection.
UR - http://www.scopus.com/inward/record.url?scp=17844362239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844362239&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2004.12.251
DO - 10.1016/j.transproceed.2004.12.251
M3 - Article
C2 - 15848578
AN - SCOPUS:17844362239
VL - 37
SP - 930
EP - 933
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 2
ER -